Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.61 |
| ▸ | POLB | P06746 | 2/20 | 0.61 |
| ▸ | CA2 | P00918 | 2/20 | 0.59 |
| ▸ | CA12 | O43570 | 1/20 | 0.59 |
| ▸ | CA1 | P00915 | 1/20 | 0.59 |
| ▸ | CA4 | P22748 | 1/20 | 0.59 |
| ▸ | CA9 | Q16790 | 1/20 | 0.59 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.59 |
| ▸ | F2 | P00734 | 3/20 | 0.57 |
| ▸ | PRSS1 | P07477 | 3/20 | 0.57 |
| ▸ | PRSS2 | P07478 | 3/20 | 0.57 |
| ▸ | PRSS3 | P35030 | 3/20 | 0.57 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.57 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.57 |
| ▸ | TSHR | P16473 | 1/20 | 0.57 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.57 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.57 |
| ▸ | PKM | P14618 | 2/20 | 0.56 |
| ▸ | PRMT1 | Q99873 | 1/20 | 0.53 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL14832025 | 0.98 | POLB (0.59) | LMNAPOLBCA2CA12CA1 | |
| SCHEMBL2242660 | 0.85 | L3MBTL1 (0.61) | LMNACA2CA12CA1CA4 | |
| SCHEMBL22916894 | 0.82 | LMNA (0.63) | LMNAPOLBCA2CA12CA1 | |
| SCHEMBL11406378 | 0.82 | LMNA (0.63) | LMNAPOLBCA2CA12CA1 | |
| SCHEMBL5566217 | 0.81 | POLB (0.57) | LMNAPOLBCA2CA12CA1 | |
| SCHEMBL1684425 | 0.80 | CA2 (0.65) | LMNACA2CA12CA1CA4 | |
| SCHEMBL31475667 | 0.80 | CA2 (0.68) | LMNACA2CA12CA1CA4 | |
| SCHEMBL7142664 | 0.80 | CA2 (0.68) | LMNACA2CA12CA1CA4 | |
| SCHEMBL922755 | 0.79 | CYP19A1 (0.66) | LMNAPOLBCA2CA12CA1 | |
| SCHEMBL2018411 | 0.79 | LMNA (0.69) | LMNAPOLBCA2CA12CA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 208 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-110857301-B | Method for preparing TNNI3K inhibitor | 南京理工大学 | 2022-07-22 | — | — | CN | claimed |
| CN-109422748-B | Method for synthesizing TNNI3K inhibitor | 南京理工大学 | 2021-06-22 | — | — | CN | claimed |
| CN-110857301-A | Method for preparing TNNI3K inhibitor | 南京理工大学 | 2020-03-03 | — | — | CN | claimed |
| EP-1451160-B1 | PYRAZOLE-AMIDES FOR USE IN THE TREATMENT OF PAIN | ICAGEN INC (US) | 2010-01-13 | — | — | EP | claimed |
| EP-1761541-B1 | PYRRAZOLO-PYRIMIDINE DERIVATIVES | HOFFMANN LA ROCHE (CH) | 2008-01-09 | — | — | EP | claimed |
| EP-1761541-A1 | PYRRAZOLO-PYRIMIDINE DERIVATIVES | F.HOFFMANN-LA ROCHE AG (CH) | 2007-03-14 | — | — | EP | claimed |
| WO-2005123738-A1 | PYRRAZOLO-PYRIMIDINE DERIVATIVES | F.HOFFMANN-LA ROCHE AG (CH) | 2005-12-29 | — | — | WO | claimed |
| US-20260078114-A1 | COMPOUND USED AS INHIBITOR OF CDK4 KINASE AND USE THEREOF | TYK MEDICINES INC (CN) | 2026-03-19 | — | — | US | disclosed |
| EP-4585595-A1 | COMPOUND USED AS INHIBITOR OF CDK4 KINASE AND USE THEREOF | TYK Medicines, Inc. (CN) | 2025-07-16 | — | — | EP | disclosed |
| US-12319676-B2 | Substituted amide compounds useful as farnesoid X receptor modulators | BRISTOL-MYERS SQUIBB COMPANY (US) | 2025-06-03 | — | — | US | disclosed |
| US-12269827-B1 | Substituted pyrazino[1′,2′:1,5]pyrazolo[4,3-c][1,6]naphthyridines as CK2 inhibitors | King Faisal University (SA) | 2025-04-08 | — | — | US | disclosed |
| US-12258345-B1 | Pyrrolo[3,2-c]isoquinoline-2,3-dione compounds as CK2 inhibitors | King Faisal University (SA) | 2025-03-25 | — | — | US | disclosed |
| WO-2025051211-A1 | COMPOUND USED AS CDK4 KINASE INHIBITOR AND USE THEREOF | 浙江同源康医药股份有限公司 | 2025-03-13 | — | — | WO | disclosed |
| WO-2003045379-A1 | HYDRAZONOPYRAZOLE DERIVATIVES AND THEIR USE AS THERAPEUTICS | KINETEK PHARMACEUTICALS, INC. (CA) | 2003-06-05 | — | — | WO | disclosed |
| EP-0372315-B1 | Reactive dyes based on copper formazane | BASF AG (DE) | 1994-01-26 | — | — | EP | disclosed |
| US-5149789-A | Triazine dyes | BASF AKTIENGESELLSCHAFT (DE) | 1992-09-22 | — | — | US | disclosed |
| US-5041540-A | For dyeing or printing hydroxyl- or nitrogen-containing substrates | BASF AKTIENGESELLSCHAFT (DE) | 1991-08-20 | — | — | US | disclosed |
| EP-0391264-A1 | Reactive dyes with two or three halogen-N-heterocycles as reactive groups | BASF Aktiengesellschaft (DE) | 1990-10-10 | — | — | EP | disclosed |
| EP-0372315-A1 | Reactive dyes based on copper formazane | BASF Aktiengesellschaft (DE) | 1990-06-13 | — | — | EP | disclosed |
| US-4153413-A | DYEING POLYESTER OR CELLULOSE TRIACETATE WITH A DISPERSE AZO DYESTUFF, HEAT TREATMENT, PADDING, PRINTING | IMPERIAL CHEMICAL INDUSTRIES LIMITED (GB) | 1979-05-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12319676-B2 | Substituted amide compounds useful as farnesoid X receptor modulators | NR1H4, FXR1, NR1H3 | LMNA 2299/4885POLB 3415/4885CA2 1816/4885 |
| US-20260078114-A1 | COMPOUND USED AS INHIBITOR OF CDK4 KINASE AND USE THEREOF | CDK4, CDK1, CDK3 | LMNA 505/4885POLB 607/4885CA2 2851/4885 |
| US-12269827-B1 | Substituted pyrazino[1′,2′:1,5]pyrazolo[4,3-c][1,6]naphthyridines as CK2 inhibitors | CSNK1A1, CSNK1G1, CSNK2A1 | LMNA 2624/4885POLB 712/4885CA2 1013/4885 |
| US-12258345-B1 | Pyrrolo[3,2-c]isoquinoline-2,3-dione compounds as CK2 inhibitors | CSNK2A3, CSNK2A1, CSNK2A2 | LMNA 3520/4885POLB 416/4885CA2 725/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.